TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00907166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-613
Description: IV infusion of CPI-613 given on Days 1,4, 8, 11, 15, 18, of 28 day cycle in cancer patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-613
Description: IV infusion of CPI-613 given on Days 1, 4, 8, 11, 15, 18, of 28 day cycle in patients with pancreatic carcinoma.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: IV infusion of 1000 mg/m\^2 of Gemcitabine given on Days 1, 8, and 15 of a 28 day cycle in patients with pancreatic carcinoma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV infusion of 1000 mg/m\^2 of Gemcitabine given on Days 1, 8, and 15 of a 28 day cycle in cancer patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV infusion of 1000 mg/m\^2 of Gemcitabine given on Days 1, 8, and 15 of a 28 day cycle in patients with pancreatic carcinoma.
Study: NCT00881465

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Description: Cognitive-Behavioral Therapy. The psychotherapy protocol will include 14 90-minute sessions of videophone administered CBT over 12 weeks.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Wait-list control
Description: Waitlist Control. The participant and his/her parents will be instructed to not obtain treatment outside of the protocol or make medication changes/additions. This will be assessed through interview at the Post-Waitlist assessment.
Study: NCT04100941

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: standard suction
Description: After the needle is inserted in the mass, removing the stylet before performing EUS-FNA. Then attach a 10mL syringe to the end of needle. 20 times of for-backward Suction was applied after the lesion was punctured.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: slow pull
Description: After the needle is inserted in the mass, slowly pull the stylet out while performing EUS-FNA with 20 times for-backward.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: wet suction
Description: After removing the stylet, the needle was flushed with 5mL of saline solution to replace the column of air with saline. A 10mL syringe was attached to the end of the needle. 20 times of for-backward Suction was applied after the lesion was punctured.
Study: NCT00820222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: oral medication; daily dose divided into morning and evening dose and taken for 14 days of 21 day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: oral medication; daily dose divided into morning and evening dose and taken for 14 days of 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: oral medication; daily dose taken once a day
Study: NCT02255500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXPAREL Infiltration
Description: A single dose of EXPAREL 266 mg expanded to 60 mL with preservative-free sterile normal saline will be infiltrated into the surgical site just prior to wound closure.
Study: NCT02994732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-BVD-523
Description: \[14C\]-BVD-523 administered as a 600-mg (approximately 200 µCi) oral dose to 6 healthy male subjects following a 2-hour fast from food (not including water) that follows breakfast.
Study: NCT02684643

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enhanced individualised therapy
Description: additional dialysis dosage, modification of medication and prescribed dietary plan
Study: NCT00820222

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab
Description: infusion therapy; loading dose of 8mg/kg, followed by 6mg/kg given every 3 weeks
Study: NCT00733096

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: Two transforaminal epidural steroid injections with 60 mg, two weeks apart
Study: NCT02854254

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: peripherally inserted central catheter
Description: peripherally inserted central catheter

Intervention type: DEVICE
Group type: OTHER
Intervention: peripherally venous access
Description: standard over-the-needle intravenous catheter
Study: NCT02434965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPDSC
Description: Autologous HPDSC collected after birth will be infused in aliquots. one-half of the HPDSC infused on Day 2; one-half of the collected HPDSC will be infused on Day 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cord blood
Description: Autologous Cord Blood collected after birth will be infused in aliquots. One-third of the collected cord blood will be infused within the first 24 hours after birth (Day 0); one-third of the collected cord blood will be infused on day 3; and one-third of the collected cord blood unit will be infused on Day 7.
Study: NCT06005519

Intervention type: OTHER
Group type: OTHER
Intervention: low AGE diet education
Description: Participants were divided into ten-person groups. Each group was individually invited for a face-to-face meeting where they were provided with a 50-minute low-AGE diet education prepared in accordance with the recommendations of the American Diabetes Association and the Turkish Society of Endocrinology and Metabolism. During the first 20 minutes of the education, a PowerPoint presentation highlighted the importance of choosing plant-based, low-AGE foods and emphasized cooking methods such as boiling, steaming, and preparing meals with added liquids. Participants were advised against frying, roasting, and grilling. Additionally, information was provided on marinade techniques and the use of spices or ingredients such as lemon or vinegar to lower pH in meals. Following the education, participants were given a dietary diary to record their food intake and were asked to self-assess their diet adherence on a scale of 1 to 10 on a weekly basis.

Intervention type: OTHER
Group type: OTHER
Intervention: low AGE diet education
Description: Participants were divided into ten-person groups. Each group was individually invited for a face-to-face meeting where they were provided with a 50-minute low-AGE diet education prepared in accordance with the recommendations of the American Diabetes Association and the Turkish Society of Endocrinology and Metabolism. During the first 20 minutes of the education, a PowerPoint presentation highlighted the importance of choosing plant-based, low-AGE foods and emphasized cooking methods such as boiling, steaming, and preparing meals with added liquids. Participants were advised against frying, roasting, and grilling. Additionally, information was provided on marinade techniques and the use of spices or ingredients such as lemon or vinegar to lower pH in meals. Following the education, participants were given a dietary diary to record their food intake and were asked to self-assess their diet adherence on a scale of 1 to 10 on a weekly basis.
Study: NCT03104257

Intervention type: DRUG
Intervention: [11-C]OMAR
Description: The radiotracer, \[11-C\]OMAR will be administered at no more than 10 micrograms at the beginning of each PET scan.

Intervention type: DRUG
Intervention: [11-C]OMAR
Description: The radiotracer, \[11-C\]OMAR will be administered at no more than 10 micrograms at the beginning of each PET scan.
Study: NCT00787501

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SSRI
Description: SSRI: 25 patients will receive 14 weeks of an FDA approved selective serotonin reuptake inhibitor (SSRI), administered under the supervision of a staff psychiatrist. After an initial 30-45 minute session patients will be seen for 15-30 minute sessions for 16-20 sessions over 14 weeks. Medication will begin with 10mg escitalopram daily (or its equivalent), increased to 30 mg/day (or its equivalent) by week 6 if pt has not achieved a minimum level of response (i.e., CGI \< 2) and tolerability is adequate. Nonresponse at week 10 (CGI \< 2) will be cause for medication switch or augmentation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Description: Cognitive Behavior Therapy: 40 patients will receive 16- 20 60 minute sessions of procedurally determined Cognitive Therapy (Beck, 1979) over 14 weeks. Patients will begin with 2 sessions per week which may be reduced to once per week in the latter part of the study period if the patient is responding to the therapy. Cognitive Therapy is designed to teach skills that help to reduce depressive severity. Each session will be videotaped and will include homework to be completed and brought to the following session.
Study: NCT01943240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paravertebral nerve block: 4 mL ropivacaine 0.5% at each of six levels

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paravertebral nerve block: 4 mL ropivacaine 0.5% at each of six levels

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 cc of 0.375% ropivacaine pectoral nerve block
Study: NCT03589755

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness meditation
Description: The intervention consist of a weekly session of mindfulness meditation provided by a clinical psychologist trained in this area. She will provide weekly session to a group of 10 patients at a time for a total of 8 weeks. Upon completing the course, the other 10 people will start
Study: NCT00705887

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Motivational Enhancement Intervention
Description: The motivational enhancement intervention lasted 5-8 minutes and consisted of gaining the client's permission to address the topic of skin cancer prevention, exchanging information through the elicit-provide-elicit strategy of information exchange, and summarization/ conclusion based on verbal and nonverbal cues from the participant.
Study: NCT00569868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: Except for the two PCR-based genotyping assays, which will be conducted only on baseline samples, tests will be assessed at baseline, 1-3 hours after the first dose of Velcade day 1 and on day 11 of the first cycle of Velcade.~The platelet Aggregation Test will be done only if Platelet count is 100 000.
Study: NCT02684643

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non-enhanced individualised therapy
Description: modified medication, prescribed dietary plan and regular three times/week dialysis dosage
Study: NCT00733096

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Two transforaminal epidural saline injections, two weeks apart
Study: NCT00440830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine patch
Description: nicotine patch (0,5,10 or 15mg/day) applied to smokers

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine patch
Description: nicotine patch (0,5,10,or 15mg/day) applied to nonsmokers

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo patch applied to smokers

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo patch applied to nonsmokers
Study: NCT01300260

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2189265
Description: Administered subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2189265
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Administered intravenously
Study: NCT02684643

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: regular intervention
Description: Phosphate binders and calcitriol would be prescribed according to the guidelines. Phosphate binders included in the study are calcium acetate, calcium carbonate or sevelamer. Dosage is based on patients serum phosphate and calcium level. Calcitriol prescribed in the study is Rocaltrol and the dosage is based on PTH, serum phosphate and calcium level. Patients' diet habit will not be altered.
Study: NCT01300260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: Administered intravenously
Study: NCT01789606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg Immediate Release/Extended Release Caplet
Description: Ibuprofen 600 mg Immediate Release/Extended Release Caplet to be adminstered orally (i.e., one caplet every 12 hours, not to exceed 2 caplets per day) for pain.
Study: NCT02667470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin
Description: Oral
Study: NCT03903939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloprost
Description: continuously infusion for 72 hours 1 ng/kg/min

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline
Description: continuously infusion for 72 hours equal volume to Iloprost
Study: NCT03180307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTL38
Description: 0.025 mg/kg of OTL38 in 250ml dextrose 5% in water (D5W) infused intravenously over 60 minutes

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: OTL38
Description: 0.025 mg/kg of OTL38 in 250ml dextrose 5% in water (D5W) infused intravenously over 60 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: near infrared camera imaging system
Description: Infrared imaging used to excite OTL38 for fluorescence

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparotomy
Description: primary surgical cytoreduction, interval debulking, or recurrent ovarian cancer surgery

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: laparotomy
Description: primary surgical cytoreduction, interval debulking, or recurrent ovarian cancer surgery
Study: NCT01909765

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dorsal slit
Description: Skin and mucosa incision made together

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Double incision
Description: Skin and mucosa incision made separately
Study: NCT04585607

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A medium cut-off dialyzer (Theranova) will be used for HDx.
Description: A medium cut-off dialyzer used for HDx (Theranova) must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required. General rules will be applied regarding dialysis prescription.~HD with MCO dialyzer (Theranova 400®, Baxter) vs. high-flux dialyzer (eg. Polyflux H, Baxter)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: A synthetic high-flux dialyzer (Polyflux)
Description: A synthetic high-flux dialyzer (Polyflux) used for hemodialysis must be implemented following current clinical practices guidelines and procedures at the hospital. No additional actions are required.
Study: NCT03401060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Each subcutaneous injection will occur every 6 months during 3 years for a total of 7 injections

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each subcutaneous injection will occur every 6 months during 3 years for a total of 7 injections
Study: NCT01354366

Intervention type: OTHER
Intervention: Infant formula

Intervention type: OTHER
Intervention: Infant formula

Intervention type: OTHER
Intervention: Infant formula
Study: NCT03507075

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency management: Contingent incentives
Description: Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions and verified abstinence from alcohol.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Contingency management: Noncontingent incentives
Description: Monetary incentives are delivered to participants contingent upon on-time breathalyzer submissions only with no contingency on alcohol use.
Study: NCT03902119

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INYBI tool
Description: Patients will lie down in supine position so that the INYBI tool will contact the suboccipital muscles at the posterior arch of the atlas. The therapist will adapt the height of the tool for each individual. All patients will use the softest head of the device. A 50Hz vibration speed will be set sup during 5 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual suboccipital inhibition
Description: Patients will lie down in supine position.The therapist will be seated at the head of the treatment table. The therapist will keep the metacarpophalangeal joints in a flexed position, while therapists fingertips of both hands will contact with the suboccipital muscles at the posterior arch of the atlas.
Study: NCT01590654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single Ascending Dose (SAD) Cohorts GS-9620
Description: This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single Ascending Dose (SAD) Cohorts GS-9620
Description: This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single Ascending Dose (SAD) Cohorts GS-9620
Description: This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single Ascending Dose (SAD) Cohorts GS-9620
Description: This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple Ascending Dose (MAD) Cohorts GS-9620
Description: This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple Ascending Dose (MAD) Cohorts GS-9620
Description: This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses).
Study: NCT01214707

Intervention type: OTHER
Intervention: Exercise
Description: Exercise during EMU stay
Study: NCT01441674

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animal Assisted Therapy
Description: There will be a therapy dog and dog trainer present working with the patient for the AAT arm.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Animal Assisted Therapy
Description: There will be a therapy dog and dog trainer present working with the patient for the AAT arm.
Study: NCT00628680

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AAT-023 solution (Zuragen)
Description: Amount equal to the catheter lumen plus 0.3mL. Three times per week (after each Hemodialysis) for 26 weeks
Study: NCT04178746

Intervention type: DEVICE
Intervention: Artemis Neuro Evacuation Device
Description: The Artemis Neuro Evacuation Device is used for the controlled aspiration of tissue and/or fluid during surgery of the Ventricular System or Cerebrum in conjunction with a Penumbra Aspiration Pump.~The Penumbra Aspiration Pump is indicated as a vacuum source for the Penumbra Aspiration Systems.~The Artemis Device will be evaluated by descriptive statistics in this registry to assess its efficiency and reliability in minimally invasive, mechanical evacuation of hematoma in patients with intracranial hemorrhage under direct visualization and control using a neuroendoscope.
Study: NCT00138944

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: od

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eplerenone
Description: 50mg od
Study: NCT00930150

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted cognitive training
Description: Adaptive computer exercises that systematically increase in task difficulty as each participant's performance ability improves

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer control
Description: Commercially available computer games selected based on quality, ability to hold interest, and lack of disturbing content

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bridging groups
Description: Weekly group meetings that help participants apply their cognitive skills to everyday functioning, promote group identity, and promote socialization

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health and wellness groups
Description: Weekly group meetings that teach participants health and wellness skills
Study: NCT03732885

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: densah burs osseo densification drills
Description: maxillary sinus floor elevation during implant placement using Densah burs

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Summer's Osteotomes
Description: maxillary sinus floor elevation during implant placement using Summer's Osteotomes
Study: NCT04009421

Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary artery plaque assessment by CT coronary angiography QAngio CT RE
Description: Assessment of segmental plaque volume and composition
Study: NCT03805932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxetumomab Pasudotox-tdfk
Description: Moxetumomab pasudotox-tdfk is administered at 30-40 ug/Kg intravenous (iv) over 30 min given on days 1, 3, 5 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxetumomab Pasudotox-tdfk
Description: Moxetumomab pasudotox-tdfk is administered at 30-40 ug/Kg intravenous (iv) over 30 min given on days 1, 3, 5 of each cycle.
Study: NCT00628680

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Hepaarin 5000 units diluted with normal saline to the exact catheter lumen volume.